Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Transplantation of an individual's own tissue from one site to another site.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The transference of a part of or an entire liver from one human or animal to another.
Progenitor cells from which all blood cells derive.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
The transference of a kidney from one human or animal to another.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Cells with high proliferative and self renewal capacities derived from adults.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
The return of a sign, symptom, or disease after a remission.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Therapeutic act or process that initiates a response to a complete or partial remission level.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Immunological rejection of leukemia cells following bone marrow transplantation.
The transference of a heart from one human or animal to another.
Cells that can give rise to cells of the three different GERM LAYERS.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
The transference of either one or both of the lungs from one human or animal to another.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
A particular zone of tissue composed of a specialized microenvironment where stem cells are retained in a undifferentiated, self-renewable state.
Self-renewing cells that generate the main phenotypes of the nervous system in both the embryo and adult. Neural stem cells are precursors to both NEURONS and NEUROGLIA.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Elements of limited time intervals, contributing to particular results or situations.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Cells from adult organisms that have been reprogrammed into a pluripotential state similar to that of EMBRYONIC STEM CELLS.
Transference of an organ between individuals of the same species or between individuals of different species.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Disorders of the blood and blood forming tissues.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
Specialized stem cells that are committed to give rise to cells that have a particular function; examples are MYOBLASTS; MYELOID PROGENITOR CELLS; and skin stem cells. (Stem Cells: A Primer [Internet]. Bethesda (MD): National Institutes of Health (US); 2000 May [cited 2002 Apr 5]. Available from:
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Cells derived from a FETUS that retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Providers of tissues for transplant to non-related individuals.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The transference of a pancreas from one human or animal to another.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Disease having a short and relatively severe course.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
The physiological renewal, repair, or replacement of tissue.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
Experimentation on STEM CELLS and on the use of stem cells.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.
Transplantation between animals of different species.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Methods for maintaining or growing CELLS in vitro.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
Transference of fetal tissue between individuals of the same species or between individuals of different species.
A general term for various neoplastic diseases of the lymphoid tissue.
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
Euploid male germ cells of an early stage of SPERMATOGENESIS, derived from prespermatogonia. With the onset of puberty, spermatogonia at the basement membrane of the seminiferous tubule proliferate by mitotic then meiotic divisions and give rise to the haploid SPERMATOCYTES.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Parts of plants that usually grow vertically upwards towards the light and support the leaves, buds, and reproductive structures. (From Concise Dictionary of Biology, 1990)
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tissues, cells, or organs transplanted between genetically different individuals of the same species.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Antibodies obtained from a single clone of cells grown in mice or rats.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Antibodies produced by a single clone of cells.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Infection with ROSEOLOVIRUS, the most common in humans being EXANTHEMA SUBITUM, a benign disease of infants and young children.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
The number of LYMPHOCYTES per unit volume of BLOOD.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
An anti-inflammatory 9-fluoro-glucocorticoid.
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
The number of CELLS of a specific kind, usually measured per unit volume or area of sample.
A family composed of spouses and their children.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
A field of medicine concerned with developing and using strategies aimed at repair or replacement of damaged, diseased, or metabolically deficient organs, tissues, and cells via TISSUE ENGINEERING; CELL TRANSPLANTATION; and ARTIFICIAL ORGANS and BIOARTIFICIAL ORGANS and tissues.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Infections with fungi of the genus ASPERGILLUS.
The transfer of leukocytes from a donor to a recipient or reinfusion to the donor.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
Pathological processes of the LIVER.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
An individual that contains cell populations derived from different zygotes.
Non-invasive imaging of cells that have been labeled non-destructively, such as with nanoemulsions or reporter genes that can be detected by molecular imaging, to monitor their location, viability, cell lineage expansion, response to drugs, movement, or other behaviors in vivo.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
A decrease in the number of NEUTROPHILS found in the blood.
A PREDNISOLONE derivative with similar anti-inflammatory action.
An octamer transcription factor that is expressed primarily in totipotent embryonic STEM CELLS and GERM CELLS and is down-regulated during CELL DIFFERENTIATION.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Transference of tissue within an individual, between individuals of the same species, or between individuals of different species.

Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. (1/3936)

Myoblasts, the precursors of skeletal muscle fibers, can be induced to withdraw from the cell cycle and differentiate in vitro. Recent studies have also identified undifferentiated subpopulations that can self-renew and generate myogenic cells (Baroffio, A., M. Hamann, L. Bernheim, M.-L. Bochaton-Pillat, G. Gabbiani, and C.R. Bader. 1996. Differentiation. 60:47-57; Yoshida, N., S. Yoshida, K. Koishi, K. Masuda, and Y. Nabeshima. 1998. J. Cell Sci. 111:769-779). Cultured myoblasts can also differentiate and contribute to repair and new muscle formation in vivo, a capacity exploited in attempts to develop myoblast transplantation (MT) for genetic modification of adult muscle. Our studies of the dynamics of MT demonstrate that cultures of myoblasts contain distinct subpopulations defined by their behavior in vitro and divergent responses to grafting. By comparing a genomic and a semiconserved marker, we have followed the fate of myoblasts transplanted into muscles of dystrophic mice, finding that the majority of the grafted cells quickly die and only a minority are responsible for new muscle formation. This minority is behaviorally distinct, slowly dividing in tissue culture, but rapidly proliferative after grafting, suggesting a subpopulation with stem cell-like characteristics.  (+info)

Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. (2/3936)

Multipotent and self-renewing neural stem cells have been isolated in culture, but equivalent cells have not yet been prospectively identified in neural tissue. Using cell surface markers and flow cytometry, we have isolated neural crest stem cells (NCSCs) from mammalian fetal peripheral nerve. These cells are phenotypically and functionally indistinguishable from NCSCs previously isolated by culturing embryonic neural tube explants. Moreover, in vivo BrdU labeling indicates that these stem cells self-renew in vivo. NCSCs freshly isolated from nerve tissue can be directly transplanted in vivo, where they generate both neurons and glia. These data indicate that neural stem cells persist in peripheral nerve into late gestation by undergoing self-renewal. Such persistence may explain the origins of some PNS tumors in humans.  (+info)

Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. (3/3936)

Many patients have not been offered potentially curative allogeneic marrow transplants because of the toxicity of myeloablative regimens in the setting of advanced age or organ dysfunction. We treated five patients, ineligible for myeloablative chemotherapy due to one of these criteria, with fludarabine-based non-myeloablative chemotherapy followed by reinfusion of G-CSF-mobilised allogeneic peripheral blood progenitor cells (PBPC). Two patients died early of multi-organ failure. Another patient with massive splenomegaly was infused with a suboptimal number of PBPC; no engraftment was documented. The remaining two patients demonstrated mixed chimerism early post-transplant, but by 3 and 6 months respectively, engraftment was almost entirely of donor origin. One of these patients, transplanted with relapsed AML, remains in remission with extensive chronic GVHD at 17 months. The other patient, transplanted with chemorefractory mantle cell lymphoma, progressed early post-transplant but entered remission coincident with the onset of severe GVHD following cessation of cyclosporin A, suggesting a powerful graft-versus-mantle cell lymphoma effect. These preliminary observations suggest this approach results in engraftment and GVHD/graft-versus-tumour effects similar to myeloablative regimens and may provide an alternative in patients ineligible for conventional conditioning regimens.  (+info)

Pattern and kinetics of mouse donor spermatogonial stem cell colonization in recipient testes. (4/3936)

Recently a system was developed in which transplanted donor spermatogonial stem cells establish complete spermatogenesis in the testes of an infertile recipient. To obtain insight into stem cell activity and the behavior of donor germ cells, the pattern and kinetics of mouse spermatogonial colonization in recipient seminiferous tubules were analyzed during the 4 mo following transplantation. The colonization process can be divided into three continuous phases. First, during the initial week, transplanted cells were randomly distributed throughout the tubules, and a small number reached the basement membrane. Second, from 1 wk to 1 mo, donor cells on the basement membrane divided and formed a monolayer network. Third, beginning at about 1 mo and continuing throughout the observation period, cells in the center of the network differentiated extensively and established a colony of spermatogenesis, which expanded laterally by repeating phase two and then three. An average of 19 donor cell-derived colonies developed from 10(6) cells transplanted to the seminiferous tubules of a recipient testis; the number of colonized sites did not change between 1 and 4 mo. However, the length of the colonies increased from 0.73 to 5.78 mm between 1 and 4 mo. These experiments establish the feasibility of studying in a systematic and quantitative manner the pattern and kinetics of the colonization process. Using spermatogonial transplantation as a functional assay, it should be possible to assess the effects of various treatments on stem cells and on recipient seminiferous tubules to provide unique insight into the process of spermatogenesis.  (+info)

Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. (5/3936)

BACKGROUND: Conditions that destroy the limbal area of the peripheral cornea, such as the Stevens-Johnson syndrome, ocular pemphigoid, and chemical and thermal injuries, can deplete stem cells of the corneal epithelium. The result is scarring and opacification of the normally clear cornea. Standard corneal transplantation cannot treat this form of functional blindness. METHODS: We performed and evaluated 70 transplantations of corneal epithelial stem cells from cadaveric eyes into 43 eyes of 39 patients with severe ocular-surface disorders and limbal dysfunction. Medical treatment had failed in all patients. The patients had a mean preoperative visual acuity of 0.004 (only being able to count the number of fingers presented by the examiner) in the affected eyes, which satisfies the criteria for legal blindness in most countries. In 28 eyes, we also performed standard corneal transplantation. Stem-cell transplantations were performed as many as four times on 1 eye if the initial results were not satisfactory; 19 eyes had multiple transplantations. Patients were followed for at least one year after transplantation. RESULTS: A mean of 1163 days after stem-cell transplantation, 22 of the 43 eyes (51 percent) had corneal epithelialization; of the 22 eyes, 7 eyes had corneal stromal edema and 15 eyes had clear corneas. Mean visual acuity improved from 0.004 to 0.02 (vision sufficient to distinguish the largest symbol on the visual-acuity chart from a distance of 1 m) (P<0.001). The 15 eyes in which the cornea remained clear had a final mean visual acuity of 0.11 (the ability to distinguish the largest symbol from a distance of 5 m). Complications of the first transplantation included persistent defects in the corneal epithelium in 26 eyes, ocular hypertension in 16 eyes, and rejection of the corneal graft in 13 of 28 eyes. The epithelial defects eventually healed in all but two of the eyes. CONCLUSIONS: Transplantation of corneal epithelial stem cells can restore useful vision in some patients with severe ocular-surface disorders.  (+info)

"Global" cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain. (6/3936)

Many diseases of the central nervous system (CNS), particularly those of genetic, metabolic, or infectious/inflammatory etiology, are characterized by "global" neural degeneration or dysfunction. Therapy might require widespread neural cell replacement, a challenge not regarded conventionally as amenable to neural transplantation. Mouse mutants characterized by CNS-wide white matter disease provide ideal models for testing the hypothesis that neural stem cell transplantation might compensate for defective neural cell types in neuropathologies requiring cell replacement throughout the brain. The oligodendrocytes of the dysmyelinated shiverer (shi) mouse are "globally" dysfunctional because they lack myelin basic protein (MBP) essential for effective myelination. Therapy, therefore, requires widespread replacement with MBP-expressing oligodendrocytes. Clonal neural stem cells transplanted at birth-using a simple intracerebroventricular implantation technique-resulted in widespread engraftment throughout the shi brain with repletion of MBP. Accordingly, of the many donor cells that differentiated into oligodendroglia-there appeared to be a shift in the fate of these multipotent cells toward an oligodendroglial fate-a subgroup myelinated up to 52% (mean = approximately 40%) of host neuronal processes with better compacted myelin of a thickness and periodicity more closely approximating normal. A number of recipient animals evinced decrement in their symptomatic tremor. Therefore, "global" neural cell replacement seems feasible for some CNS pathologies if cells with stem-like features are used.  (+info)

The lung in the immunocompromised patient. Infectious complications part 2. (7/3936)

Pulmonary infections decisively contribute to morbidity and mortality in immunocompromised patients. Bacterial, mycobacterial and infections with Pneumocystis carinii have been reviewed in an article in the last issue of Respiration. In this review, viral and fungal pulmonary infections are discussed in HIV-positive patients and in patients treated with high-dose chemotherapy, stem cell or solid-organ transplantation.  (+info)

Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. (8/3936)

As in other malignancies, peripheral blood progenitor cells (PBPC) have almost completely replaced bone marrow as the source of stem cells for autologous transplantation in multiple myeloma. PBPC collection could be optimized either by reducing contamination by the malignant clone or by increasing hematopoietic quality of the graft. Currently, the most promising technique for purifying the harvest is CD34 cell selection. Several pilot studies have shown the feasibility of this method in MM. However controlled studies are necessary to assess the clinical impact of CD34+ cell selection. In the IFM 94 study, CD34+ selection was optional. There was no significant difference between 50 patients receiving a CD34+ selected graft and 133 patients receiving non-selected PBPC, as regards duration of neutropenia, duration of thrombocytopenia, response rate, EFS or survival. Hematopoietic recovery after transplantation is related to the number of CD34+ cells infused. The optimal regimen for mobilizing the requested CD34+ yield is not yet known. We have completed a randomized study comparing the combination of SCF plus G-CSF and G-CSF alone after priming with cyclophosphamide 4 g/m2. The median number of leukaphereses to reach the target yield of 5x10(6) CD34+ cells/kg was 1 in the SCF group (N=55) versus 2 in the G-CSF group (N=47) (p=0.008). The median number of CD34+ cells collected in the first leukapheresis was 11. 6x10(6) in the SCF group versus 4x10(6) in the G-CSF group (p=0.003). These results are in line with those observed in other trials testing the combination of SCF and G-CSF to improve PBPC collection.  (+info)

These techniques developed by the Stem Cells for Hope Clinics are being applied to implement treatments for a wide range of human degenerative and debilitating conditions, including neurodegenerative diseases, ocular disease and various physiological injuries. Our Global Network of Clinics, who have been treating patients for the last 15 to 18 years, are also involved in ongoing human Stem Cell Research and the Development of new Stem Cell Transplantation Therapy protocols and they are currently successfully treating patients with this Regenerative Medical technology outside of the United States.. Stem Cells for Hope does not have any treatment facilities nor do we treat any patients inside the United States or any other countries where Stem Cell Transplantation Therapy is not approved by the local Government Health Administration.. Please see the Stem Cells for Hope [Medical Forms] for a checklist of medical information that we will require.. Our experienced International Medical and Scientific ...
TY - JOUR. T1 - Regeneration of the central nervous system using endogenous repair mechanisms. AU - Okano, Hideyuki. AU - Sakaguchi, Masanori. AU - Ohki, Koichi. AU - Suzuki, Norihiro. AU - Sawamoto, Kazunobu. PY - 2007/9. Y1 - 2007/9. N2 - Recent advances in developmental and stem cell biology have made regeneration-based therapies feasible as therapeutic strategies for patients with damaged central nervous systems (CNSs), including those with spinal cord injuries, Parkinson disease, or stroke. These strategies can be classified into two approaches: (i) the replenishment of lost neural cells and (ii) the induction of axonal regeneration. The first approach includes the activation of endogenous neural stem cells (NSCs) in the adult CNS and cell transplantation therapy. Endogenous NSCs have been shown to give rise to new neurons after insults, including ischemia, have been sustained; this form of neurogenesis followed by the migration and functional maturation of neuronal cells, as well as the ...
Mainstream of current treatment of liver cirrhosis is liver transplantation, but there are high cost, risk and immune rejection and other issues. Umbilical cord mesenchyma stem cell with self-and directed differentiation capacity can effectively rescue experimental liver failure and contribute to liver regeneration, which suggests the feasibility of stem cell transplantation therapy. In this study, the safety and efficacy of umbilical cord mesenchyma stem cell transplantation through interventional procedures in patients liver cirrhosis will be evaluated ...
Abstract. Results obtained from completed and on-going clinical studies indicate huge therapeutic potential of stem cell-based therapy in the treatment of degenerative, autoimmune and genetic disorders. However, clinical application of stem cells raises numerous ethical and safety concerns.. In this review, we provide an overview of the most important ethical issues in stem cell therapy, as a contribution to the controversial debate about their clinical usage in regenerative and transplantation medicine.. We describe ethical challenges regarding human embryonic stem cell (hESC) research, emphasizing that ethical dilemma involving the destruction of a human embryo is a major factor that may have limited the development of hESC-based clinical therapies. With previous derivation of induced pluripotent stem cells (iPSCs) this problem has been overcome, however current perspectives regarding clinical translation of iPSCs still remain. Unlimited differentiation potential of iPSCs which can be used in ...
Gene replacement strategy and Southern blot analysis of progeny from heterozygous crosses. (a) The wild-type P-selectin allele, the replacement vector, and th
LONDON, Aug. 24, 2020 /PRNewswire/ -- The global stem cell technologies and applications market is estimated to have reached US $17,791.8 million 2020 and ...
Thanks so much to the editors at Vogue Brazil for acknowleging 3LAB Perfect C Serum in their December 2009 issue! The article, on the marvels of apple stem cell technology in skincare, looks at the newest technology and their favorite products that contain it. Thanks so much! ...
By Dr. Kieran OSullivan, University of Limerick, Ireland. And Prof. Peter OSullivan, Curtin University, Australia. The 14-time Grand Slam winner, Rafael Nadals recent struggles to participate at the highest level due to ongoing low back pain (LBP) once again brings the issue of novel therapies offering tantalizing cures to the fore; he is undergoing stem cell therapy (SCT). So it is timely to explore: i) what this therapy potentially offers, ii) the quality of the supporting evidence, iii) its comparison to other needle-based therapies, and iv) what the use of several novel needle-based therapies in the last decade (e.g. stem cell therapy, platelet-rich plasma, dry needling) reveal about attitudes to management of pain in sporting populations.. What is stem cell therapy and why consider it?. Stem cell therapy (SCT) has opened up exciting avenues in health research across many disciplines. Focusing on the role of SCT in LBP, its proposed mechanism of action is regeneration of local spinal ...
However, the FDA is constantly reviewing various other types of stem cell therapy and some of them may receive approval as you are reading this article. A stem cell therapy Highlands Ranch clinic professional suggests that as a basic safety precaution, patients should always ask whether the therapy they propose to undertake has been reviewed by the FDA. Also, ask for clarifications whenever you do not understand something.. Precautions Concerning Travelling Abroad for Stem Cell Therapy. Some patients are lured by promises of more affordable costs for stem cell therapy in other countries. The first thing to remember is that the FDA has no oversight of therapies, treatments and medical procedures performed outside the territory of the USA.. Therefore, patients should always weigh the affordability of the treatment against safety and the possibility to obtain relief in case of malpractice.. ...
Autoimmune Diseases and the Promise of Stem Cell-Based Therapies One of the more perplexing questions in biomedical research is-why does the bodys
Check out the best hospitals for Bone Marrow Stem Cell Therapies in Orange, United States. Avail Top Stem Cell Therapy Packages at cheap prices.
Unearth 100+ Medical Centers for Bone Marrow Stem Cell Therapies in Castletown,United Kingdom. Avail Top Stem Cell Therapy Packages at cheap prices.
Taking Organ Transplantation to 2020: A UK strategy has been launched by NHS Blood and Transplant and the four UK health departments. The strategy sets the agenda for increasing organ donation and transplantation rates to world class standards over the next seven years and builds on success in increasing deceased
Youll always face risks when puncturing the skin for any test or procedure. With proper techniques and guidelines infection is exceedingly rare, only about 1 in 1000 are affected at all by infection. Stem cell therapy and growth factor injections are very safe, but still always ensure youre working with the best of doctors and only doing things you understand and are comfortable with. Medicine always comes with risks, the best thing you can do for yourself is research the topic so you know what youre talking about and doing to your body. It is most important to work with a team of skilled medical professionals in stem cell therapy. You can trust NeoGenix Stem Cell Therapy to provide you with a safe and effective procedure.. ...
Stem cell therapies offer great hope to patients with debilitating illnesses and injuries. However, only a limited number of therapies are approved for clinical use. At this event, a panel of experts described the stem cell therapy landscape. The discussants also highlighted the available treatments today, described why even negative clinical data can lead to new interventions, and evaluated recent incidents of unregulated stem cell use harming patients.. This event was part of an annual policy lecture series co-sponsored by the Baker Institute Center for Health and Biosciences and the Texas Heart Institute. Support for the program has been provided by a grant from the George and Mary Josephine Hamman Foundation. Follow @BakerCHB on Twitter and join the conversation online with #BakerStemCell ...
R. Lee Buckler, vice president of business and corporate development at RepliCel Life Sciences Inc., has been an executive in the cell therapy sector since 2000, beginning with Malachite Management in the Stem Cell Technologies group of companies. Most recently he was the managing director of Cell Therapy Group, a firm he formed in 2008 to do business development consulting for companies and organizations working in or interested in the cell therapy sector. His work included deal-targeting, transactions, market intelligence, competitive analyses, strategic assessments and market profile planning for companies ranging from top-tier multinationals to start-ups. Buckler served six years as executive director of the International Society for Cellular Therapy and just over two years as director of business development for Progenitor Cell Therapy. Buckler has a bachelors degree in education, and a law degree. He is on the editorial advisory boards of the journalRegenerative Medicine and the ...
This first systematic evaluation of randomized controlled trials utilizing PMR plans for weight management suggests that these types of interventions can safely and effectively produce significant sustainable weight loss and improve weight-related risk factors of disease.
Find regenerative approach treatment copd. Mississsippi Stem Cell Therapy Center promotes stem cell therapy and regenerative medicine.
Are you considering stem cell therapy to help treat your spinal pain? What you should know about stem cell therapy before pursuing this treatment.
Stem cell therapy takes advantage of your own bodys natural healing power. Advanced research has shown that stem cell therapy is highly effective in spine surgery.
Stem Cell Therapy is becoming more popular thanks to positive testimonials from clients who have trailblazed the biotech frontier with IV and stem cell therapy injections.
Learn about the cost of stem cell therapy. This article describes the costs associated with stem cell therapy in popular countries
Get a free review from one of Americas leading stem cell therapy doctors, Dr. John Parks Trowbridge, serving the Houston, Texas area and beyond!
Poor survival and function of transplanted cells in ischemic and inflamed myocardium likely compromises the functional benefit of stem cell-based therapies. We have earlier reported that co-administration of interleukin (IL)−10 and BMPAC enhances cell survival and improves left ventricular (LV) functions after acute myocardial infarction (MI) in mice. We hypothesized that IL-10 regulates microRNA-375 (miR-375) signaling in BMPACs to enhance their survival and function in ischemic myocardium after MI and attenuates left ventricular dysfunction after MI. miR-375 expression is significantly upregulated in BMPACs upon exposure to inflammatory/hypoxic stimulus and also after MI. IL-10 knockout mice display significantly elevated miR-375 levels. We report that ex vivo miR-375 knockdown in BMPAC before transplantation in the ischemic myocardium after MI significantly improve the survival and retention of transplanted BMPACs and also BMPAC-mediated post-infarct repair, neovascularization, and LV ...
A new study describes a new synthetic hybrid molecule that can selectively target and eliminate pluripotent cells and reduce the tumorigenic threat of cell transplantation strategies
HSCI does not enroll any volunteers in clinical trials. Currently, the only stem cell-based treatment that is routinely reviewed and approved by the U.S. Food and Drug Administration (FDA) is hematopoietic (or blood) stem cell transplantation. It is used to treat patients with cancers and disorders that affect the blood and immune system. Stem cell-based therapies for all other conditions are still experimental.
In the collaboration, Plasticell will use its CombiCult technology to screen combinations of molecules provided by GSK to identify and optimise iPSC differentiation protocols.
Researches carried out by Cambridge University showed possibility for same sex reproduction, according to the study published in Cell.
Stem cell regenerative therapies hold great promise for patients suffering from a variety of disorders that are associated with tissue or organ injury. Regeneration relies on tissue or organ-specific stem and progenitor cells, but can also aim at promoting the endogenous repair capacity of the body. Mesenchymal stromal cells (MSC) are undergoing clinical testing in a variety of clinical conditions aiming at repair through direct or indirect mechanisms. Their ability to form bone or cartilage is used to directly repair these tissues. In other conditions their regenerative effects are based on endogenous repair through their anti-inflammatory properties. The latter mechanism is important in the treatment of acute Graft-versus-Host Disease (GvHD). We have been involved in the clinical development from the beginning and we have shown the therapeutic potential. However, no results of controlled randomized phase 3 studies have been published to date, thereby hampering safety and efficacy ...
Mesoblast shares up two per cent on evidence its stem cell therapy can reduce deaths in children with a complication from bone marrow transplants.
Question - Have diabetes. Is there any operation or stem cell therapy for it?. Ask a Doctor about Kidney transplantation, Ask a Diabetologist
Regenerative medicine researchers successfully attempted stem cell therapy to repair damaged heart muscle in non-human primates.. ...
At PAINWeek 2017, Dr Joshi gave on overview of stem cell therapies used in regenerative medicine to treat a number of pain conditions.
Learn more about stem cell therapy and regenerative medicine at Spectrum Health Medical Clinic. Find answers to help you improve your life today and live pain free.
Stem cell therapy in Miami have a huge healing potential and have became one of the most popular regenerative medicine treatments in recent years.
A new device that can rapidly concentrate and extract young cells from irrigation fluid used during orthopaedic surgery holds promise for improving the delivery of stem cell therapy in cases of non-healing fractures. UC Davis surgeons plan to launch a proof-of-concept clinical trial to test the safety and efficacy of the device in the coming months.
Engineering Stem Cell Therapies for Heart Repair on Wyss Institute | No therapy currently available can reduce the size of an established scar on the heart.
Scientists who investigated a case of stem cell therapy to treat kidney disease are warning of a new type of complication not seen before, the development of blood vessel and bone marrow masses, the long term effects of which are unknown.
New research has opened the possibility of a new, less invasive lung surgery. This could be the best solution to COPD and similar lung diseases. Find out if stem cell therapy is an effective treatment option for you and your lung disease!
Phase 1 study of stem cell therapy for multiple sclerosis finds no safety issues or signs of disease activation - plus enticing hints of benefits to be explored in phase 2 testing.
Autism is known as the complex brain disorder. This disorder can cause some problems such as the difficulty in communication which can lead to impaired social interactions. In addition, this kind of disorder can cause the acts of obsessive repetition or routine.. The general problem which most of children with autism face is hypoxia. This problem is mainly caused by the condition in which the brain is lack of oxygen. It can cause the immune system not to work appropriately as those with sufficient oxygen.. There are several treatments that are innovative as well as alternative therapies introduced and used over the years ...
Principios fundamentales de la Terapia Celular aplicada al miocardio/Essential concepts of Stem Cell Therapy applied to myocardium ...
The first major concern about the safety and efficacy of stem cell therapy depends on where and by whom the treatments are being performed.
Stem cell therapy is a very important breakthrough in the field of healthcare in India. It has shown remarkable results in various medical conditions.
Dr. Megan Strauchman of the Natural Wellness & Pain Relief Center is among the first physicians in Genesee County to offer stem cell therapy to patients.
Stem cell therapy might provide a remedy for acquired immunodeficiency syndrome (AIDS) after it was used on an HIV patient in Germany, the first person known to have been cured of the disease, a Department of Health (DOH) official said Tuesday.
Dr. Bruce Ruben & Encompass Healthcare & Wound Medicine in West Bloomfield is Michigans #1 infection & wound care facility for stem cell therapy.
The Power That Created The Body Is The Power That Heals The Body Stem Cell Therapy is offering alternatives and hope to many patients who suffer from chronic
AIIMS-Patna achieved a major feat on Wednesday by performing first stem cell therapy in Bihar. A very rare experiment done in select hospitals of the count
AIIMS-Patna achieved a major feat on Wednesday by performing first stem cell therapy in Bihar. A very rare experiment done in select hospitals of the count
"Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... "Peripheral stem cell support", is a method of replacing blood-forming stem cells. Stem cells can be destroyed through cancer ... "Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation". 2005-09-09. Welte, K; Gabrilove, J; Bronchud, MH; ... The administered hematopoietic stem cells then migrate to the recipient's bone marrow, through a process known as stem cell ...
Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-117. doi:10.1634/stemcells.19-2- ... Stem-cell transplantation was pioneered using bone marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... Thomas' hematopoietic cell transplantation: stem cell transplantation. 5th ed. Vol. 2. New Jersey: Wiley-Blackwell; 2016. p. ...
... is a procedure in which a patient receives blood-forming stem cells (cells from which all ... Syngeneic stem cell transplantation entry in the public domain NCI Dictionary of Cancer Terms This article incorporates public ... blood cells develop) donated by his or her healthy identical twin. ... Organ transplantation, All stub articles, Surgery stubs). ...
Autologous hematopoietic stem-cell transplantation Stem-cell therapy "What Are Stem Cells?". Retrieved 2017-02-12. Mahla RS ( ... is autologous transplantation of stem cells-that is, transplantation in which stem cells (undifferentiated cells from which ... Autologous stem-cell transplantation is distinguished from allogenic stem cell transplantation where the donor and the ... Autologous stem-cell transplantation (also called autogenous, autogeneic, or autogenic stem-cell transplantation and ...
... and nucleated cells. The adult stem cell fraction is present in the nucleated cells of the marrow. Most of these cells are ... As a result, many researchers have focused on adult stem cells, or stem cells isolated from adult humans that can be ... Mesenchymal stem cells were originally discovered and studied as fibroblast-colony forming cells in guinea-pig bone marrow and ... There are five types of stem cells and MSC's are multi-potent meaning they are cells that have the ability to develop into more ...
"Conditions stem cell transplant can cure". INDHEAL. (Stem cells). ... Hematopoietic stem cell transplantation may be used to treat a number of conditions both congenital and acquired. Malignancies ... "Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation". N Engl J Med. 360 (7): 692-698. doi:10.1056/ ... Immunodeficiencies T-cell deficiencies Ataxia-telangiectasia DiGeorge syndrome Combined T- and B-cell deficiencies Severe ...
Hematopoietic stem cell transplantation (HSCT) involves intravenous infusion of stem cells to those who have either a damaged ... Hematopoietic stem cells give rise to blood cells. Differentiation and proliferation of hematopoietic stem cells require a lot ... Stem cells are taken from an affected child's blood or bone marrow. Then in laboratory conditions the stem cells are ... RD can only be treated temporarily through hematopoietic stem cell transplantation (HSCT) and cytokine therapy. Transplantation ...
Hematopoietic stem cell transplantation remains the only curative treatment for CMML. However, due to the late age of onset and ... Robert J. Soiffer (17 November 2008). Hematopoietic Stem Cell Transplantation. Springer. ISBN 978-1-934115-05-3. Retrieved 23 ... Unlike MPNs, MDSs have a dysfunctional production of myeloid cells with a reduced number of mature cells. Many of the cells ... as well as abnormal looking cells (dysplasia) in at least one type of blood cell. CMML shows characteristics of a ...
Fish JD, Grupp SA (January 2008). "Stem cell transplantation for neuroblastoma". Bone Marrow Transplantation. 41 (2): 159-165. ... "Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma". Biology of Blood and Marrow Transplantation. ... Treatments may include observation, surgery, radiation, chemotherapy, or stem cell transplantation. Low-risk disease in babies ... October 2007). "Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation ...
"Stem cell transplantation for primary immunodeficiencies". Bone Marrow Transplantation. 41 (S2): S83-S86. doi:10.1038/bmt. ... cell responses to mitogens and allogeneic cells, cytokine production by cells Tests for B cell function: antibodies to routine ... Virus-specific T-lymphocytes (VST) therapy is used for patients who have received hematopoietic stem cell transplantation that ... Induced pluripotent stem cells obtained reprogramming patients' cells, for example leukocytes, are a promising tool to study ...
He went through Stem Cell Transplantation. Upon a relapse he had in 2013, he sought medical treatment at Hadassah Hospital ...
Or-Geva, N; Reisner, Y (March 2016). "The evolution of T-cell depletion in haploidentical stem-cell transplantation". British ... Booth, Claire (2013). "The Current Role of T Cell Depletion in Paediatric Stem Cell Transplantation". British Journal of ... "Overview of T-cell depletion in haploidentical stem cell transplantation". Blood Transfusion. 10 (3): 264-272. doi:10.2450/ ... "What is Haploidentical Stem Cell Transplantation?". 2017-01-09. Ni, Xiong; Song, Qingxiao; Cassady, Kaniel; Deng, Ruishu; Jin, ...
Gaziev, J; Lucarelli, G (June 2011). "Hematopoietic stem cell transplantation for thalassemia". Current Stem Cell Research & ... 2011). "T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients". Pediatric Reports. 3 ( ... Sharma, Akshay; Jagannath, Vanitha A.; Puri, Latika (21 April 2021). "Hematopoietic stem cell transplantation for people with β ... The procedure involves collecting hematopoietic stem cells (HSCs) from the affected person's blood. The HSCs then have a beta- ...
For services to Stem Cell Transplantation. Vivianne Frances Brealey. Deputy Director of Communications, Public Health England. ... For services to Science and Public Engagement in STEM. Professor Robert John Allison. Vice-Chancellor, Loughborough University ... For services to Chemistry, Commercialisation and Promoting Diversity in STEM. Alexander Murray Russell. Chief Executive Officer ...
PMID 28326337 Orchard PJ, Fasth AL, Le Rademacher J, et al (2015). "Hematopoietic stem cell transplantation for infantile ... The only effective line of treatment for malignant infantile osteopetrosis is hematopoietic stem cell transplantation. It has ... have demonstrated bone remodeling and recanalization of medullar canals following hematopoietic stem cell transplantation. This ... radiographic pathology in a case of malignant infantile osteopetrosis following hematopoietic stem cell transplantation". Egypt ...
Riley, Unell (2009). Treleaven, Jennifer; Barrett, A John (eds.). Hematopoietic Stem Cell Transplantation in Clinical Practice ...
272-. ISBN 978-93-5152-415-1. N. K. Mehra (5 July 2011). "Hematopoietic Stem Cell Transplantation : Opportunities and ... List of foreign recipients of the National Order of Merit Hematopoietic stem cell transplantation Diabetes mellitus type 1 ... He sits on the National Board of Advisors of the Center for Stem Cell Science, and the Advisory Board of Indus Foundation and ... "National Board of Advisors". Center for Stem Cell Science. 2017. Archived from the original on 21 January 2020. Retrieved 8 ...
"Dry eye after haematopoietic stem cell transplantation". The British Journal of Ophthalmology. 83 (10): 1125-30. doi:10.1136/ ... Since iron is a major component of bacterial cell walls, removal of iron breaks down the cell wall, which in turn breaks down ... Secretory cells are found in a group, or acinus. Each acinus is located at the terminal part of the gland connected to the ... Each acinus consists of a single layer of cuboidal epithelial cells surrounding a lumen, a central opening where the saliva is ...
Hematopoietic stem cell transplantation may be curative. Winter, Harland. "Autoimmune Enteropathy: My infant patient has ... This test is done to look at the stomach and small intestines and to see what cells are infiltrating the digestive tract. There ...
The number of pregnancies observed after hematopoietic stem cell transplantation involving such a procedure is lower than 2%. ... Tichelli André, Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) ... preventing immunologic rejection of transplanted donor bone marrow or blood stem cells. Additionally, high doses of total body ...
Stem cell transplantation is being studied and has shown promising results in certain cases. Medical trials to replace the ... Blood cells are produced in the bone marrow by stem cells that reside there. Aplastic anaemia causes a deficiency of all blood ... The expression of 1,25-(OH)2D3 can be induced by macrophages, dendritic cells, T-cells, and B-cells. In the presence of 1,25-( ... Targeted cells include: red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. Based on increased or ...
The only prospect for a permanent cure is the high-risk option of an allogeneic hematopoietic stem cell transplantation (SCT). ... Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK (2001). "Allogeneic stem cell transplantation for Evans syndrome". ... Martino R, Sureda A, Brunet S (1997). "Peripheral blood stem cell mobilization in refractory autoimmune Evans syndrome: a ... The symptoms of Evans syndrome vary between patients depending on which blood cells are affected. If red blood cells are ...
Tichelli André; Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... Tichelli André; Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... a special type of cell division specific to germ cells, produces egg cells in women. During meiosis, accurate segregation of ... and the number of pregnancies observed after hematopoietic stem cell transplantation involving such as procedure is lower than ...
"Stem cell transplantation in chronic lymphocytic leukemia". Biology of Blood and Marrow Transplantation. 15 (1 Suppl): 53-58. ... Some people who successfully respond to treatment also undergo stem cell transplantation to consolidate the response. Treatment ... One such approach used genetically modified T cells, known as chimeric antigen receptor T cells (CAR-T cells), to attack cancer ... Large granular lymphocytic leukemia may involve either T-cells or NK cells; like hairy cell leukemia, which involves solely B ...
"Breakthrough in stem cell transplantation of eye". The Hindu. 31 October 2001. Retrieved 16 December 2017.[dead link] "List of ... of adult limbal stem cells and their applications in treating ocular surface disorders caused by limbal stem cell deficiency". ... Vemuganti is reported to have done pioneering work in stem cell therapy and was a member of the team led by V. S. Sangwan that ... doi:10.1016/s0161-6420(02)01088-6. Keratitis Stem cell therapy India portal Medicine portal Please see Selected bibliography ...
Journal of Stem Cell Therapy and Transplantation. 1 (1): 008-016. doi:10.29328/journal.jsctt.1001002. Robertus JL, Harms G, ... Rhabdomyoblasts are early stage mesenchymal cells, having the potential to differentiate into a wide range of skeletal cells. ... As maturation and differentiation progress, the cell's cytoplasmic levels of white blood cells increase; additionally, ... These neoplastic cells yield positive results for vimentin, smooth muscle actin, and desmin stains; however, myoglobin, myoD1 ...
Hematopoietic stem cell transplantation (HSCT) with high intensity conditioning protocol has been performed in a few cases with ... There is a limited but encouraging therapeutic experience of hematopoietic stem cell transplantation for SPS. Patients with ... "Autologous Stem Cell Transplantation for Stiff Person Syndrome". JAMA Neurology. 71 (10): 1296-9. doi:10.1001/jamaneurol. ... "Autologous haematopoietic stem cell transplantation for neurological diseases". J Neurol Neurosurg Psychiatry. 89 (2): 147-155 ...
March 1997). "Factors predicting morbidity following hematopoietic stem cell transplantation". Bone Marrow Transplantation. 19 ... Stem cell markers are genes and their protein products used by scientists to isolate and identify stem cells. Stem cells can ... 2005). "Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors". Stem Cells. 23 (6 ... "Integrins are markers of human neural stem cells". Stem Cells. 24 (9): 2078-84. doi:10.1634/stemcells.2005-0595. PMID 16690778 ...
... autologous hematopoietic stem cell transplantation is sometimes performed. The treatment may induce long-term remission even in ... "Autologous haematopoietic stem cell transplantation for neurological diseases". Journal of Neurology, Neurosurgery, and ... which targets B cells, and cyclophosphamide, a drug which reduces the function of the immune system. Ciclosporin has also been ...
Autologous hematopoietic stem cell transplantation (HSCT) is sometimes used in severe, treatment-refractory MG. Available data ... Cell Stem Cell. 18 (1): 134-143. doi:10.1016/j.stem.2015.10.002. PMC 4707991. PMID 26549107. Zhang Z, Guo J, Su G, Li J, Wu H, ... neuromuscular junction assay from human embryonic stem cells and somatic-muscle stem cells. After the addition of pathogenic ... Burman J, Tolf A, Hägglund H, Askmark H (February 2018). "Autologous haematopoietic stem cell transplantation for neurological ...
... is often used clinically to quantify the number of haemopoietic stem cells for use in haemopoietic stem cell transplantation. ... May 2018). "Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ ... CD34 was first described on hematopoietic stem cells independently by Civin et al. and Tindle et al. as a cell surface ... It is important to mention that Long-Term Haematopoietic Stem Cells (LT-HSCs) in mice and humans are the haematopoietic cells ...
... and stem cell transplantation. Pediatric cancers are treated by specialists at the UPMC Children's Hospital of Pittsburgh. The ...
... and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation ... "Toward personalized medicine in renal transplantation". Transplantation Proceedings. 42 (8): 2864-7. doi:10.1016/j.transproceed ...
Jha, Alok (2 April 2007). "British team grows human heart valve from stem cells". The Guardian. London. Retrieved 23 November ... Fisher, Andrew (6 June 2018). "Andrew Fisher on Magdi Yacoub: The icon at the heart of UK organ transplantation". British ... it was reported that a British medical research team led by Yacoub had grown part of a human heart valve from stem cells. In ... 2004: International Society for Heart and Lung Transplantation Lifetime Achievement Award, at the 24th annual meeting in San ...
... indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplantation ... It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell ... Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to ... 2004). "Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or ...
... and haemorrhagic cystitis in haematopoietic stem cell transplant recipients. Decoy cells can be seen in a urine sample through ... Transplantation. 85 (9): 1311-7. doi:10.1097/TP.0b013e31816c4ec5. PMC 3796953. PMID 18475189. Koss LG. On decoy cells. Acta ... Decoy cells are virally infected epithelial cells that can be found in the urine. Decoy cells owe their name to their strong ... In our experience, these features make decoy cells different from tubular cells and transitional cells found in all other ...
"Use of T-allo10 Cell Infusions Combined With Mismatched Related or Mismatched Unrelated Hematopoietic Stem Cell Transplantation ... Roncarolo has made major contributions in the field of cell and gene therapy. She performed fetal stem cell transplants given ... Smith Professor in Stem Cell and Regenerative Medicine and Professor of Medicine (Blood and Marrow Transplantation and Cellular ... She is also the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine along with Irving Weissman ...
Royan International Research Award nominations for the best five research papers in reproductive biomedicine and stem cells at ... Organ transplantation Iván González Cancel is a cardiovascular and thoracic surgeon who is credited with the realization of the ... In 2007 he was awarded a Luminary Award by HENAAC (now Great Minds in STEM) for excellence in engineering, and a Star Award by ... There he conducted research that would make him the foremost expert on cell makeup of the human eye lens. Alcalá developed ...
These simple transplantation methods follow from earlier observations by developmental biologists that germ stem cells are ... Cell Stem Cell. 23 (5): 665-676.e4. doi:10.1016/j.stem.2018.09.004. ISSN 1934-5909. PMID 30318303. (All articles with dead ... In usual circumstances, when foreign cells (such as cells or organs from other people, or infectious bacteria) are put into a ... "Repopulation of testicular Seminiferous tubules with foreign cells, corresponding resultant germ cells, and corresponding ...
... because cord blood is rich in blood stem cells. Blood stem cells are young or immature cells that can transform into other ... in order to support cord blood transplantations and related research in Singapore and around the world. SCBB is registered in ... matched stem cell units because of the relative scarcity of stem cell donors that matched Singapore's main ethnic profiles i.e ... such as red blood cells, white blood cells and platelets. The use of blood stem cells has emerged as a potentially curative ...
"Complications of hematopoietic stem transplantation: Fungal infections". Hematology/Oncology and Stem Cell Therapy. 10 (4): 239 ... It works by affecting fungal metabolism and fungal cell membranes. Voriconazole was patented in 1990 and approved for medical ... squamous cell skin cancer, and Stevens-Johnson syndrome; in long-term use there is a warning of the risk of bone fluorosis and ... World Journal of Transplantation. 11 (9): 356-371. doi:10.5500/wjt.v11.i9.356. PMC 8465512. PMID 34631468. "Vfend loses its ...
Allogeneic stem cell transplantation can induce durable remissions for heavily pre-treated patients. As of October 2010, there ... Yang L, Wen B, Li H, Yang M, Jin Y, Yang S, Tao J (1999). "Autologous peripheral blood stem cell transplantation for ... lymphoplasmacytoid cells and plasma cells. Both cell types are white blood cells. It is characterized by having high levels of ... "Allogeneic Stem-Cell Transplantation in Patients with Waldenstrom Macroglobulinemia: Report from the Lymphoma Working Party of ...
... which lend themselves better to the embryonic stem cell techniques typically used for genetic manipulation. Many investigators ... Research applications include transplantation research, induced arthritis and inflammation, experimental allergic encephalitis ... and C-cell adenomas/adenocarcinomas of the thyroid gland and tumors of the haemopoietic system in males. Second, Lewis rats are ... and gain weight from an increase in both the size and number of fat cells. Obesity in Zucker rats is primarily linked to their ...
She was subsequently treated with allogenic stem cell transplantation and had complete resolution of symptoms. One year post- ... The virus activates a subset of T-helper cells called Th1 cells. The result is a proliferation of Th1 cells and overproduction ... including CD8+ T cells, dendritic cells and B cells. HTLV-I entry is mediated through interaction of the surface unit of the ... Human T-cell lymphotropic virus type 1 or human T-lymphotropic virus (HTLV-I), also called the adult T-cell lymphoma virus type ...
... therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation". Cancer. ... increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation". Blood ... the intensity diminishing with maturation of stem cells. Common side effects of administration included shivering, fever, ... CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, ...
... immortalized human cell lines and stem cells. The purpose of BAL-type devices, currently, is not to permanently replace liver ... Orthotopic liver transplantation is the only treatment that has shown to improve acute and chronic complications derived from ... Liver cells obtained from an animal were used instead of developing a piece of equipment for each function of the liver. The ... However, in the cell-seeded reactor there was an increase in the levels of ammonia, which the researchers stated could be ...
... internationally recognized for his work on human umbilical cord blood as a source of transplantable hematopoietic stem cells. ... In 1988, he first coordinated a study in successfully demonstrating clinical utility of cord blood transplantation to cure a ... Work from his laboratory established the field of clinical cord blood transplantation. He died from thyroid cancer on 8 ... 1989 Oct 26; 321(17): 1174-8 Indiana University's Hal Broxmeyer, pioneer of cord blood transplantation, dies at 77 "E Donnall ...
T cells are not the only immune cells affected by aging: Hematopoietic stem cells (HSC), which provide the regulated lifelong ... which can be achieved by transplantation of proliferative thymic epithelial cells from young mice. Metformin has been proven to ... April 2015). "Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination". Science ... October 2004). "Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells". Nature. 431 ( ...
Bianchi, DW; Fisk, NM (2007). "Fetomaternal cell trafficking and the stem cell debate: gender matters". JAMA. 297 (13): 1489- ... Messerlian says, including cancer, transplantation and in vitro fertilization protocols, and research she is conducting is ... dividing and changing into the cells needed to fix the problem. This has led to a field of study known as fetal cell ... While the work proved challenging due to the relative rarity of the fetal cells in the mother's blood, the research led to an ...
One emerging therapy is hematopoietic stem cell transplantation, which has been considered standard treatment for many combined ... Patients with WHIM syndrome have severely reduced peripheral blood B cells and some reduction in peripheral blood T cells and ... normally a catastrophic event in which chromosomes undergo massive deletion and rearrangement within a single stem cell's DNA, ... Cell. 160 (4): 686-699. doi:10.1016/j.cell.2015.01.014. PMC 4329071. PMID 25662009. Booth, Jonathan C.; Kumar, Umesh; Webster, ...
An advantage to this approach is that a person's own stem cells are used, avoiding tissue rejection by the immune system. Stem ... Arumugam, S (2007). "Transplantation of autologous chondrocytes ex-vivo expanded using Thermoreversible Gelation Polymer in a ... Because mesenchymal stem cells may regenerate cartilage, cartilage growth in human knees using autologous cultured mesenchymal ... 10,000 cells are harvested and grown in vitro for approximately six weeks until the population reaches 10-12 million cells. ...
There are advancements that are happening with blood stem cell research. Once the advances are made and patients can be treated ... Bone marrow transplantation (BMT) can cure hematological aspects of DBA. This option may be considered when patients become ... The phenotype of DBA patients suggests a hematological stem cell defect specifically affecting the erythroid progenitor ... A diagnosis of DBA is made on the basis of anemia, low reticulocyte (immature red blood cells) counts, and diminished erythroid ...
Stem Cell Transplantation Center Minimal Invasive Endoscopic Surgery Center Elderly Care Unit Center Child Development Center ... bone marrow transplantation project It also houses modern operating rooms and intensive care units. The third building is ...
Successful stem cell transplantation was achieved in mice without irradiation after 3 weeks on a valine restricted diet. Long- ... December 2016). "Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation". Science. 354 ... Dietary valine is essential for hematopoietic stem cell (HSC) self-renewal, as demonstrated by experiments in mice. Dietary ... July 2016). "Branch-Chain Amino Acids Improves Metabolic Health". Cell Reports. 16 (2): 520-530. doi:10.1016/j.celrep.2016.05. ...
... platelet activation in vascular disease and stem cell transplantation in cancer patients. Publications in endocrinology cover ... Lopez A, Caragol I, Candeias J, Villamor N, Echaniz P, Ortuno F, Sempere A, Strauss K, Orfao A. Enumeration of CD4+ T-cells in ... The staging and prognostic value of subset markers on CD8 cells in HIV disease. In Janossy G, Autran B. Miedema F (eds): ... His interest in immunology has led to publications in HIV disease, cellular activation and natural killer cell function, tumor ...
Furthermore, plant extracts of water spinach inhibit cancer cell growth of Vero, Hep-2 and A-549 cells, though have moderate ... Its stems are 2-3 metres (7-10 ft) or longer, rooting at the nodes, and they are hollow and can float. The leaves vary from ... Six weeks after sowing the seedlings, cuttings for transplantation can be taken from them. One cutting is an approximately 30 ... The stems and bottom of the edible portion of the plant are higher in concentration and should be removed to minimize the heavy ...
... during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic stem cell transplantation". ... Andersen was the accounting firm most identified with the scandals, having been indicted on criminal charges stemming from its ... CD25+ cells". Journal of Cardiothoracic Surgery. 7: 26. doi:10.1186/1749-8090-7-26. PMC 3338095. PMID 22445281. "In Belarus, ... for electrically monitoring the activity of a brain cell in a locust while that locust was watching selected highlights from ...
Stem cell transplantation is an important avenue for SCI research: the goal is to replace lost spinal cord cells, allow ... Types of cells being researched for use in SCI include embryonic stem cells, neural stem cells, mesenchymal stem cells, ... olfactory ensheathing cells, Schwann cells, activated macrophages, and induced pluripotent stem cells. Hundreds of stem cell ... A key avenue of SCI research is research on stem cells, which can differentiate into other types of cells-including those lost ...
Suresh H. Advani, oncologist who pioneered Hematopoietic stem cell transplantation in India. Dr Gurmukh Das Jagwani, former ...
Allogeneic hematopoietic stem cell transplantation provides the most powerful antileukemic effect in the treatment of acute ... Cite this: Treatment of Acute Myeloid Leukemia With Hematopoietic Stem Cell Transplantation - Medscape - May 01, 2009. ... transplantation provides a means to rescue patients from agents that may eliminate normal hematopoietic stem cells as well as ... While many investigators are understandably excited by recent progress in the identification of leukemic stem cells[90] and ...
Stem Cell Transplantation. Hematopoietic stem cell transplantation (HSCT), which includes the transfer of bone marow, mobilized ... Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the ... Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical ... Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated ...
The image below illustrates an algorithm for typically preferred hematopoietic stem cell transplantation cel... ... infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune ... Hematopoietic stem cell transplantation (HSCT) involves the intravenous (IV) ... encoded search term (Hematopoietic Stem Cell Transplantation (HSCT)) and Hematopoietic Stem Cell Transplantation (HSCT) What to ...
... of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in ... A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for ... Afterward, the collected stem cells are re-infused back into the patient to re-establish the blood-forming system. ... During ASCT, a patients own blood-forming stem cells are collected, and he or she is then treated with high doses of ...
The two main types of stem cell transplantation are *Allogeneic stem cell transplantation, using stem cells from a matched or ... Allogeneic Stem Cell Transplantation. This is the most common type of stem cell transplantation used to treat AML. Allogeneic ... These new stem cells restore healthy stem cells in the bone marrow that can form new red blood cells, white blood cells and ... Autologous stem cell transplantation, using stem cells from the patient collected before chemotherapy ...
stem cell transplantation Clinical Research Trial Listings on CenterWatch ... T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients ... TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation ... stem. cell. transplantation. (allo-. HSCT. ) is a potentially curative therapy for many malignant or nonmalignant hematological ...
... can cause significant pulmonary morbidity and mortality in hematopoietic stem cell (HSCT) and less often in solid-organ ... Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation Curr Infect Dis Rep. ... can cause significant pulmonary morbidity and mortality in hematopoietic stem cell (HSCT) and less often in solid-organ ...
Epidermal stem cells from an adult patient affected by LAM5-β3-deficient JEB were transduced with a retroviral vector ... Cultured keratinocyte stem cells, known as holoclones3,4,5,6, generate sheets of epithelium used to restore severe skin, ... site analysis indicated that the regenerated epidermis is maintained by a defined repertoire of transduced stem cells. These ... The continuous renewal of human epidermis is sustained by stem cells contained in the epidermal basal layer and in hair ...
Alzheimers Disease Stem Cells - Cord Blood Parkinsons Disease Stem Cells - Fundamentals Parkinsons Disease Surgical Treatment ... through transplantation of mesenchymal stem cells. Few studies are reported on the therapeutic effect of adipose-derived stem ... Stem Cell Transplantation can Stimulate Generation of Neurons Following Alzheimers Disease Personalised Printable Document ( ... Genetics and Stem Cells Bone Marrow Transplantation Tissue Engineering and Regenerative Medicine Transplantation Organ Donation ...
Bone marrow contains immature cells called stem cells. Stem cells can mature into blood cells (white blood cells, red blood ... it is referred to as peripheral blood stem cell transplantation (PBSCT).. For a stem cell transplant, stem cells from the ... Stem cell transplantation for Hodgkins disease usually involves harvesting the patients stem cells, from the bone marrow or ... The chemotherapy kills healthy cells as well. The transplanted stem cells replace the missing disease-free cells. ...
Stem cell transplantation in adults: lymphoma. Haematopoietic Stem Cell Transplantation-ESH/EBMT Handbook, 2nd edn, chapter ... Table 1 Summary of studies on auto hematopoietic stem cell transplantation and allo hematopoietic stem cell transplantation in ... Key Words: Mycosis fungoides, Sèzary syndrome, Stem cell transplantation Core tip: Some cutaneous T-cell lymphoma patients ... Hematopoietic stem cell transplantation (HSCT) is a procedure in which hematopoietic progenitor cells obtained from bone marrow ...
Stem cell transplantation into mouse cochlea may impact future hearing loss therapies ... Fates of murine pluripotent stem cell-derived neural progenitors following transplantation into mouse cochleae. Cell Transplant ... Stem cell transplantation into mouse cochlea may impact future hearing loss therapies. ... The authors noted that embryonic stem cells have previously been identified as promising candidates for transplantation, ...
S39-41 Haematopoietic stem cell transplantation for thalassaemia in Chinese patients CK Li, Vincent Lee, Matthew MK Shing, TF ... Advances in transfusion and iron chelation improve survival but haematopoietic stem cell transplantation (HSCT) is still the ... The result of unrelated-donor bone marrow transplantation is in general inferior but extended HLA matching may improve outcome ... Sibling cord blood and bone marrow transplantation has similar outcome. Recently alternative donor transplant has been ...
High-Dose Chemotherapy and Autologous Stem Cell Transplantation Improves Responses in Advanced Follicular Lymphoma ... Autologous Stem Cell Transplantation Improves Responses. High-Dose Chemotherapy and Autologous Stem Cell Transplantation ... All blood cells are derived from a common cell called the stem cell, which is produced in the bone marrow. The high doses of ... Autologous Stem Cell Transplants Promising for Follicular LymphomaAutologous Stem Cell Transplants By CancerConnect. Mar 8, ...
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (PALOMA). The ... Allogeneic stem cell transplantation (alloHCT) is considered the only potentially curative treatment option for MDS patients ... CCR before allogeneic blood cell transplantation (alloHCT) as first line treatment in patients with higher risk MDS and ... conventional care regimens before allogeneic blood cell transplantation as first line treatment in patients with higher risk ...
Infused MSCs became localised predominantly in peritubular areas and acted to reduce renal cell death. In conclusion, these ... when followed by MSC transplantation, significantly improved injured renal function parameters, as evidenced by decreased blood ... Mesenchymal stem cells (MSCs) are recognised as a promising tool to improve renal recovery in experimental models of cisplatin- ... "Mesenchymal stem cells in the Whartons jelly of the human umbilical cord," Stem Cells, vol. 22, no. 7, pp. 1330-1337, 2004. ...
Here, we assessed red blood cell (RBC) adhesiveness, intensity of hemolysis, vascular tone markers and systemic inflammation, ... Nevertheless, systemic inflammation persists for at least five years after transplantation, indicating that allo-HSCT does not ... Here, we assessed red blood cell (RBC) adhesiveness, intensity of hemolysis, vascular tone markers and systemic inflammation, ... Nevertheless, systemic inflammation persists for at least five years after transplantation, indicating that HSCT does not ...
Cell Stem Cell (2016) Transplanted Human Stem Cell-Derived Interneuron Precursors Mitigate Mouse Bladder Dysfunction and ... and cell fate of stem cell-derived MGE cell transplants in the uninjured rodent spinal cord. We have now obtained preliminary ... and cell fate of stem cell-derived MGE cell transplants in the uninjured rodent spinal cord. We have now obtained preliminary ... Californias Stem Cell Agency California Institute for Regenerative Medicine. * For Researchers * Funding Opportunities * ...
2018 The European Society for Blood and Marrow Transplantation. All rights reserved ...
... stem cell transplantation, Stem Cells. You Might Also Like:. * Stem Cell Transplantation Shown to Improve Outcomes in Systemic ... Stem Cell Transplantation Benefits Patients with Scleroderma. Stem Cell Transplantation Benefits Patients with Scleroderma. ... Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis. *The ACRs State-of-the-Art Clinical Symposium: Stem ... Careful Management Improves Safety of Stem Cell Transplantation in Crohns. * Recent Trials Investigated Targeted Therapies for ...
Stem cell transplantation significantly improves prognosis. Autologous peripheral blood stem cell transplantation can ... In addition, the prognoses of tandem autologous stem cell transplantation and single autologous stem cell transplantation ... Myeloablative chemotherapy and stem cell transplantation. Autologous peripheral blood stem cell collection was performed after ... stem cell transplantation is a huge financial burden for most families, which is why some patients choose to undergo stem cell ...
Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (Third Edition). Member Price: $99.00 ... Although there are multiple lines of available therapies and ongoing clinical trials, autologous stem cell transplantation ... Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. ... Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation ...
Copyright © 2022 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health. All rights reserved.. ...
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.. ... in patients with highly emetogenic chemotherapy.Hematopoietic stem cell transplantation (HSCT) is associated with infectious ...
Autologous Stem Cell Transplantation (ACST). Learn the risks and benefits of ACST, a key part of a personalized treatment plan ... CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.. By ... This program has a special focus on immunologic therapy in the setting of autologous stem cell transplantation for myeloma. ... CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. ...
The ERS-education website provides centralised access to all educational material produced by the European Respiratory Society. It is the worlds largest CME collection for lung diseases and treatment offering high quality e-learning and teaching resources for respiratory specialists. This distance learning portal contains up-to-date study material for the state-of-the-art in Pulmonology.
Acute kidney injury and mortality in hematopoietic stem cell transplantation: A single-center experience. Indian J Nephrol 27: ... Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation. Matthew H. Abramson, Victoria ... Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation. Chin J Cancer ... Our study showed a high incidence of AKI in 64% of patients undergoing allogeneic hematopoietic stem cell transplantation, with ...
Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation ... Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation ... Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation ...
Hematopoietic stem cell transplantation (HSCT) has evolved for ,20 years as a specific treatment of patients with autoimmune ... Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. ... 20 more authors) (2017) Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe ... disease (AD). Using European Society for Blood and Marrow Transplantation registry data, we summarized trends and identified ...
Keywords: Medicine, Issue 138, Colectomy, cell sheet, adipose tissue-derived stem cells, cell transplantation, cell therapy, ... Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model. DSpace/ ... ASCs formed cell sheets in thermo-responsive culture dishes that could be easily detached. On the day of the transplantation, a ... Stem cell therapy using ASC sheets could provide a solution to this problem. ASCs are considered as promising candidates for ...
  • Gene therapy offers the advantages of reduced toxicity from conditioning as, in general, less chemotherapy is required and the use of autologous cells removes the risk of graft versus host disease which causes significant morbidity and mortality post HSCT. (
  • Hematopoietic stem cell transplantation (HSCT), which includes the transfer of bone marow, mobilized CD34+ cells from peripheral blood, or umbilical cord-derived CD34+ cells, is currently the only definitive treatment for XLP syndrome. (
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (
  • Respiratory syncytial virus (RSV), one of the most common causes of respiratory infections in immunocompetent individuals, can cause significant pulmonary morbidity and mortality in hematopoietic stem cell (HSCT) and less often in solid-organ transplant recipients. (
  • Advances in transfusion and iron chelation improve survival but haematopoietic stem cell transplantation (HSCT) is still the only curative treatment. (
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only currently available curative treatment for sickle cell disease (SCD). (
  • Here, we assessed red blood cell (RBC) adhesiveness, intensity of hemolysis, vascular tone markers and systemic inflammation, in SCD patients treated with allogeneic HSCT. (
  • Nevertheless, systemic inflammation persists for at least five years after transplantation, indicating that allo-HSCT does not equally affect all aspects of SCD pathophysiology. (
  • The oral, fixed-combination NEPA containing netupitant and palonosetron target crucial pathways involved in both acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients with highly emetogenic chemotherapy.Hematopoietic stem cell transplantation (HSCT) is associated with infectious complications, especially bloodstream infections (BSI). (
  • Busulfan (BU) is a bi-functional DNA - alkylating agent used in patients undergoing hematopoietic stem cell transplantation (HSCT). (
  • His research programme is aimed at understanding and developing effective therapies for inflammatory neurological diseases, particularly multiple sclerosis (MS). His scientific contributions include studies of T cell repertoires in health and autoimmune disorders, and the elucidation of the mechanisms of action of immuno-modulatory treatments and haematopoietic stem cell transplantation (HSCT) in MS. (
  • Ideally, an allogeneic stem cell transplant will generate a new immune system for the patient. (
  • This type of transplantation may be a treatment option for older patients who cannot tolerate the high doses of chemotherapy used in preparation for a standard allogeneic stem cell transplant. (
  • The conditioning therapy used for a reduced-intensity transplant is of lower intensity than that for a standard stem cell transplant. (
  • If PBSCs are used in the transplant, it is referred to as peripheral blood stem cell transplantation (PBSCT). (
  • For a stem cell transplant, stem cells from the peripheral blood or bone marrow are collected (harvested) and placed in frozen storage prior to treatment of the cancer with high-dose chemotherapy. (
  • If your own stem cells are used the transplant is called autologous. (
  • If a donor's cells are used, it is called and allogeneic transplant. (
  • Cell Transplant. (
  • Researchers have developed a way in which to replenish the low levels of blood cells following high-dose therapy, called an autologous stem cell transplant. (
  • Previous studies have demonstrated that treatment with high-dose chemotherapy and a stem cell transplant could cure some patients with follicular lymphoma who would otherwise be considered incurable with conventional chemotherapy. (
  • Treatment consisted of intensified induction chemotherapy followed by high-dose chemotherapy and an autologous stem cell transplant. (
  • However, the long-term survival of children assigned to the high-risk group is still poor, even under a comprehensive treatment regimen including intensive induction chemotherapy, surgery, radiotherapy, myeloablative chemotherapy with autologous stem cell transplant, and immunotherapy [ 3 - 5 ]. (
  • Design, setting, participants, & measurements We performed a single-center, retrospective study of 616 allogeneic hematopoietic cell transplant recipients from 2014 to 2017. (
  • Conclusions AKI post-hematopoietic cell transplant remains a major concern. (
  • In this review, we will summarize the role of vitamin D in normal hematopoiesis, discuss ways in which vitamin D may improve outcomes, and discuss a potential role of vitamin D for treating hematologic disorders and modulating the immune system to improve the outcome of allogeneic stem cell transplant. (
  • The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. (
  • Treatment with androgens and hematopoietic (blood cell) growth factors can help bone marrow failure temporarily, but the long-term treatment is bone marrow transplant if a donor is available. (
  • Regarding the treatment of high-risk patients, autologous stem cell transplantation remains the standard of care in transplant-eligible candidates. (
  • When a patient needs a stem cell transplant, the physician's goal is to find donor stem cells that match the patient's Human Leukocyte Antigens, also known as HLA type. (
  • However, when matching cord blood cells are given together with haploidentical donor cells in a haplo-cord transplant, the two stem cell sources support each other and produce a better outcome than either alone. (
  • Our blood and marrow transplantation specialist deliberated with Demier's parents and decided to proceed with a stem cell transplant when he was 3. (
  • When his leukemia relapsed, Brown was subjected to a second stem cell transplant. (
  • The Young Professionals in Transplantation (YPT) is the Network for Junior Transplant professionals of ESOT, representing all young transplant clinicians and scientists who are beginning a career in transplantation and organ donation. (
  • Thanks to the procedure, during which stem cells were harvested from a healthy donor, a bone marrow transplant was performed in Belgium, saving the life of a patient who suffered from a potentially terminal blood-related disease. (
  • With the successful completion of our first-ever stem cell harvesting procedure, which made possible a life-saving bone marrow transplant in Belgium, the decade-long work of our donors and volunteers has once again been rewarded. (
  • Commenting on the significance of the stem cell harvesting procedure on June 16, Dr. Avagyan said that from now on stem cell donors in Armenia and neighboring countries will no longer need to travel to Europe or elsewhere for harvesting procedures, as these will be performed in Yerevan, helping considerably reduce the cost of a bone marrow transplant. (
  • Using this technology, they demonstrated for the first time that it is possible to transplant biliary cells grown in the lab into damaged human livers to repair them. (
  • Association of polymorphic MHC microsatellites with GVHD, survival, and leukemia relapse in unrelated hematopoietic stem cell transplant donor/recipient pairs matched at five HLA loci. (
  • Killer cell immunoglobulin-like receptor polymorphisms in HLA-identical kidney transplant recipients: lack of 2DL2 and 2DS2 may be associated with poor graft function. (
  • Researchers revealed that they were able to stimulate the process of neurogenesis in the brain of adult rat or mouse models with Alzheimer's disease (AD) through transplantation of mesenchymal stem cells. (
  • Mesenchymal stem cells (MSCs) are recognised as a promising tool to improve renal recovery in experimental models of cisplatin-induced acute kidney injury. (
  • Over the last decade, mesenchymal stem cells (MSCs) were shown to be one of the promising tools to treat acute kidney injury (AKI) in various animal models, including cisplatin-induced nephrotoxicity [ 1 - 3 ]. (
  • Adult mesenchymal stem cells [MSCs] are multipotent stromal cells that can give rise to several cell types such as bone, muscle, cartilage, fat, and other tissues. (
  • Mesenchymal stem cells are considered an ideal cell source for transplantation. (
  • Our body fat is rich in mesenchymal stem cells [although it occurs in various concentrations in almost every tissue in the human body]. (
  • Our treatments use mesenchymal stem cells found predominantly in fatty tissue. (
  • Originally, mesenchymal stem cells were thought to be the drivers of tissue regeneration. (
  • Like Navy Seals, these mesenchymal stem cells are very specialized, parachuted (injected) into a hostile area, and may well not survive. (
  • Cultured mesenchymal stem cells with IL-17 make them grow twice as fast. (
  • Although there are multiple lines of available therapies and ongoing clinical trials, autologous stem cell transplantation remains the central option for prolonging durations of remission and improving overall survival. (
  • Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients. (
  • Extracorporeal membrane oxygenation may serve as rescue therapy in refractory acute respiratory distress syndrome but has not been assessed in allogeneic hematopoietic stem cell transplantation recipients. (
  • Patients: All allogeneic hematopoietic stem cell transplantation recipients treated with venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome between 2010 and 2015. (
  • On the contrary, longterm allogeneic hematopoietic stem cell transplantation recipients otherwise eligible for full-code ICU management may be potential candidates for extracorporeal membrane oxygenation therapy in case of severe acute respiratory distress syndrome failing conventional measures. (
  • External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients. (
  • Further, this study aims to improve the clinical outcomes of allogeneic hematopoietic stem cell transplantation recipients. (
  • Engraftment of white blood cells and platelets was on median day 9 (range day 8-11) and patients were discharged from hospital on mean day 11 (range day 8-13). (
  • At the Hospital General Universitario Gregorio Marañon, in Madrid, our research on cord blood transplants is focused on ways to combine cord blood stem cells with other donated stem cells so that patients will receive a full cell dose and will have faster engraftment. (
  • Haplo-cord transplants have been shown to reduce the patient's engraftment time, because the haploidentical donor cells engraft faster than the cord blood cells. (
  • However, this engraftment is transient, and only acts as a bridge - eventually the stem cells from the cord blood donor take over, replace the haploidentical donor cells, and engraft permanently. (
  • This ability to reduce blood sugar levels correlated to ALDHhi cell engraftment in the mouse bone marrow, but not engraftment into the mouse pancreas. (
  • Can we engineer reselected cells to improve migration and engraftment after transplantation? (
  • Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. (
  • During ASCT, a patient's own blood-forming stem cells are collected, and he or she is then treated with high doses of chemotherapy. (
  • First the patient receives intensive chemotherapy, with or without radiation, to kill the remaining leukemic cells in the patient's body. (
  • This also destroys the normal stem cells in the patient's bone marrow. (
  • The goal is to have the donor stem cells become established in the patient's bone marrow and produce white blood cells that will attack the patient's remaining cancer cells. (
  • The cells are returned to the patient's body after receiving intensive chemotherapy. (
  • An alternative therapeutic strategy to more directly address the T cell-dependent clinical manifestations of XLP1 is gene correction of the patient's own T cells. (
  • Stem cell transplantation for Hodgkin's disease usually involves harvesting the patient's stem cells, from the bone marrow or blood, rather than from a donor. (
  • The value of tandem autologous stem cell transplantation is worthy of further discussion, which should consider various aspects such as the transplantation medication regimen and the patient's state. (
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (
  • But the biggest disadvantage of cord blood transplants is that it takes longer for the stem cells from cord blood donations to "engraft", so that the patient's immune system recovers. (
  • Successful transplantation of organs and living tissues depends on continued medical follow-up and the patient's compliance with a regimen of immunosuppressive drugs. (
  • In one case zinc finger nucleases were used to delete the CCR5 gene in a patient's cells, a procedure that we discussed in TWiV #278 . (
  • The transplantation was performed successfully on June 18, saving the Belgian patient's life. (
  • This means that the patient's own cells from disease-spared areas could be used to repair destroyed ducts. (
  • In stem cell transplantation, doctors replace a patient's bone marrow with stem cells from a healthy, fully-matched donor (usually a sibling). (
  • The National Heart, Lung, and Blood Institute is leading a nationwide study to test the effects of an experimental gene therapy to treat sickle cell disease that involves removing a patient's bone marrow and then adding copies of a correctly spelled gene for normal hemoglobin to generate normal red blood cells. (
  • For each of these therapies, chemotherapy drugs are given first to rid the body of the cancer cells. (
  • Many disorders, like type II diabetes, or Parkinson's, might one day be treatable with stem cell-based therapies, and scientists are working on creating such therapeutics. (
  • The Sarthy Lab seeks to improve the lives of children with cancer by studying the fundamental mechanisms cancer cells use to evade therapies and develop resistance. (
  • By focusing on chromatin, the mix of proteins and DNA that are found in cells ranging from yeast to fruit flies to humans, we will understand how cancers form and identify safer ways to kill cancer cells while minimizing side effects of these often toxic therapies. (
  • With intellectual property for human cord blood as a source of stem cells, Saneron is committed to providing readily available, non-controversial, ethically acceptable cells, both stem cells and other cell types, for cellular therapies. (
  • PLEASE NOTE: Due to the large number of enquiries competing for limited time, Dr Muraro regrets he is unable to reply to emails or phone calls from individuals seeking advice on therapies, stem cell treatments or participation in clinical trials. (
  • The mission of ECTORS is to provide a forum for discussing and stimulating novel developments in the fields of cellular therapies in organ transplantation, organ regeneration and generation of new organs from stem cells and biomaterials. (
  • As anticipated, poor serologic responses have been particularly observed among patients receiving B-cell depleting therapies. (
  • Cell-based therapies could provide an advantageous alternative, but the development of these new therapies is often impaired and delayed by the lack of an appropriate model to test their safety and efficacy in humans before embarking in clinical trials. (
  • Embryonic stem cell (ESC) differentiation has the potential to be instrumental in cell based therapies and in vitro disease modeling and chemical screens. (
  • Therefore, successful in vitro differentiation protocols to be applied either for cell based therapies or disease modeling should produce neurons with defined generic and subtype identity. (
  • Gene and cell therapies present novel alternatives to disease management, offering the promise of a single treatment and a lifelong cure. (
  • Background: Autologous non-myeloablative haemopoietic stem cell transplantation is a method to deliver intense immune suppression. (
  • We evaluated the safety and clinical outcome of autologous non-myeloablative haemopoietic stem cell transplantation in patients with relapsing-remitting multiple sclerosis (MS) who had not responded to treatment with interferon beta. (
  • Peripheral blood haemopoietic stem cells were mobilised with 2 g per m 2 cyclophosphamide and 10 μg per kg per day filgrastim. (
  • The conditioning regimen for the haemopoietic stem cells was 200 mg per kg cyclophosphamide and either 20 mg alemtuzumab or 6 mg per kg rabbit antithymocyte globulin. (
  • We also sought to investigate the safety and tolerability of autologous non-myeloablative haemopoietic stem cell transplantation. (
  • Interpretation: Non-myeloablative autologous haemopoietic stem cell transplantation in patients with relapsing-remitting MS reverses neurological deficits, but these results need to be confirmed in a randomised trial. (
  • The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection. (
  • Haemopoietic stem cell transplantation for genetic disorders. (
  • Although previous recommendations for preventing transmission of human immunodeficiency virus (HIV) through transplantation of human tissue and organs have markedly reduced the risk for this type of transmission, a case of HIV transmission from a screened, antibody-negative donor to several recipients raised questions about the need for additional federal oversight of transplantation of organs and tissues. (
  • Organ Transplantation.2 These Guiding Principles - whose emphases include voluntary donation, noncommercialization, genetic relation of recipients to donors and a preference for cadavers over living donors as sources - have considerably influenced professional codes, national, state and provincial legislation, and the policies of intergovernmental organizations. (
  • Corneas obtained from older donors, corneas with higher donor endothelial cell density, and corneas transplanted to older recipients demonstrated greater percentage of loss of endothelial cell density 1 year after surgery. (
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (
  • CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. (
  • The goal of this educational program is to enhance the efficacy and safety of stem cell mobilization for donors of patients with multiple myeloma (MM) by spreading information of the most current and effective methods to physicians. (
  • La información en esta página debería ser considerada como ejemplos de información de antecedentes para la temporada de influenza 2021-2022 para la práctica médica respecto del uso de medicamentos antivirales contra la influenza. (
  • Incidence of AKI post-hematopoietic transplantation is high, from 16% ( 3 ) to 85% ( 4 ), depending on the definition ( Supplemental Table 1 ). (
  • Left ventricle systolic dysfunction in young survivors after allogeneic haematopetic stem cell transplantation. (
  • Our aim is to define outcomes after hematopoietic stem cell transplantation for mycosis fungoides and Sèzary syndrome. (
  • The use of allogeneic hematopoietic stem cell transplantation continues to increase worldwide ( 1 ), with improving overall outcomes ( 2 ). (
  • Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. (
  • Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. (
  • Primary outcomes were progression-free survival and reversal of neurological disability at 3 years post-transplantation. (
  • Early immune surveillance to predict cytomegalovirus outcomes after allogeneic hematopoietic stem cell transplantation Jintao Xia, et al. (
  • Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. (
  • Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. (
  • Impact of vitamin D receptor gene polymorphisms on clinical outcomes of HLA-matched sibling hematopoietic stem cell transplantation. (
  • Transplantation appears destined to provide the most effective curative therapy for many patients with AML in the foreseeable future. (
  • Allogeneic stem cell transplantation (alloHCT) is considered the only potentially curative treatment option for MDS patients and is therefore often considered the standard treatment for mainly higher-risk MDS patients up to the age of 75 years. (
  • Background: Allogeneic hematopoietic stem cell transplantation (alloHCT) is potentially curative but with known negative effects on quality of life. (
  • Our scientists pursue every aspect of cancer research-from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more. (
  • Pembrolizumab blocks PD-1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells. (
  • The new immune system also has the potential to recognize and attack any remaining cancer cells. (
  • The transplanted immune cells (the graft) perceive the leukemia cells in the body as foreign and destroy them. (
  • A serious risk of allogeneic and reduced-intensity allogenic stem cell transplantation is graft versus host disease (GVHD) , which develops if the donor's immune cells attack your normal tissue. (
  • Rivat et al reported a preliminary study in mice in which the immune function defects of XLP syndrome were corrected by lentiviral vector-mediated gene transfer of SH2D1A into autologous hematopoietic stem cells. (
  • The authors noted that embryonic stem cells have previously been identified as promising candidates for transplantation, however they have also been associated with immune rejection and ethics issues. (
  • This causes overcrowding of blood and lymph tissue, suppressing the formation and function of blood and immune cells that are normally present. (
  • Treatment for follicular lymphoma includes chemotherapy, radiation therapy, stem cell transplantation and/or biologic therapy (treatment used to stimulate the immune system to fight cancer). (
  • Recently it has been demonstrated that MSC secreted factors have beneficial effects in various immune disorders, including transplantation rejection and graft-versus-host diseases (GVHD) [ 9 - 11 ]. (
  • By secreting factors that mute the immune system, the MSC-pericytes inhibit T-cell surveillance of the damaged tissue and bioactive agents are released by MSCs that establish a regenerative microenvironment. (
  • There has been debate as to whether Langerhans cell histiocytosis and Erdheim-Chester disease are inflammatory, immune disorders, or cancer-like conditions. (
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (
  • When the disease did not respond to chemotherapy, Brown underwent stem cell transplantation, which involves treatment with cytotoxic drugs and whole-body irradiation to destroy leukemic and immune cells, followed by administration of donor stem cells to restore the immune system. (
  • The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma that has come back or continued to grow despite one regimen of prior therapy. (
  • After the chemotherapy, the patient receives an infusion of stem cells to replace the stem cells destroyed by the intensive therapy. (
  • Patients with B-cell lymphomas should be treated with the standard therapy for that disease. (
  • Given the potential for tumorigenesis, they concluded that the source of iPS cells is a critical issue for iPS cell-based therapy. (
  • They also noted the need for developing methods to eliminate undifferentiated cells after neural induction in order to establish safe iPS-based therapy for the inner ear. (
  • According to a recent article published in the journal Blood , high-dose chemotherapy and autologous stem cell transplantation as initial therapy produces a complete disappearance of cancer in a significant number of patients with advanced follicular lymphoma. (
  • Stem cells are collected from the patient either before or sometime during treatment, frozen and re-infused following therapy. (
  • The SCOT trial enrolled patients with severe scleroderma who had severe internal organ disease (as opposed to solely skin disease) and treated them with myeloablative therapy followed by CD34+ selected autologous hematopoietic stem cell transplantation . (
  • Stem cell therapy using ASC sheets could provide a solution to this problem. (
  • We now have a tool to determine whether stem cell therapy will be efficacious for an individual patient, not only for the heart but for any organ that received stem cell therapy. (
  • Hepatic cell therapy has become a viable alternative to liver transplantation for life-threatening liver diseases. (
  • Recent advances targeted towards the differentiation of human embryonic stem cells (hESCs) or reprogrammed human induced pluripotent stem cells (hiPSCs) to various cell lineages offer significant promise for in vitro studies and as a source of viable cells for use in therapy. (
  • Saneron CCEL Therapeutics Inc. is a biotechnology research company focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases lacking adequate treatment options. (
  • At post transplantation day plus 3, antibiotic drug therapy was switched from piperacillin/tazobactam to meropenem. (
  • Persons undergoing chemotherapy and radiation therapy, which destroy the patient s bone marrow, can have their stem cells harvested for later transfusion. (
  • This approach could be applied to other organs and diseases to accelerate the clinical application of cell-based therapy. (
  • This study therefore confirmed that their cell-based therapy could be used to repair damaged livers. (
  • The scientists called their blood test a 'liquid biopsy,' and they used it with a rat model in which human cardiosphere-derived cells (CDCs) and cardiac progenitor cells (CPCs) were transplanted into hearts after myocardial infarction. (
  • Mobilized peripheral blood haematopoietic progenitor cells are increasingly being used as against bone marrow (BM) transplants, following high dose chemotherapy and/or radiotherapy for the management of chemosensitive malignancies. (
  • Globally, it is estimated that 120 000 corneal transplantations and 18 000 transplantations of allogeneic haematopoietic progenitor cells took place in the year 2000. (
  • Quite how these stem cells promote regeneration will require further assessment, but as we now have the means to amplify and assess large number of functional progenitor cells in vitro, this strategy could develop into an important approach to battle diabetes. (
  • Expanded Hematopoietic Progenitor Cells Reselected for High Aldehyde Dehydrogenase Activity Demonstrate Islet Regenerative Functions. (
  • Now a team of scientists has developed a repeatable, non-invasive, timely technique to know if transplanted stem cells are repairing damaged heart tissue. (
  • Circulating exosomes were found to carry cell parts to the muscle cells targeted in the heart, and resulted in repair of the cardiac tissue. (
  • These cells normally lie dormant in the collagen matrix of the fat but can be released and activated to repair damaged tissue. (
  • When injected into tissue, the stem cells tend to act in two main ways: first, by dividing and regenerating the aged tissue and secondly by secreting factors that help the surrounding cells to regenerate the tissue. (
  • First is the realization that this class of cells can be isolated from almost every tissue in the human body. (
  • The number of human tissue transplants is increasing in both developed and developing countries, but global data on this form of transplantation are less complete. (
  • Follow-up studies in 2011, including biopsies from his brain, intestine, and other organs, showed no signs of HIVÂ RNA or DNA, and also provided evidence for the replacement of long-lived host tissue cells with donor-derived cells. (
  • EDTCO aims to support health care professionals to provide clinically effective programmes on organ and tissue donation, procurement and transplantation. (
  • The treating clinician or pathologist may use cryopreserved cells or nucleic acid, nondecalcified formalin fixed paraffin-embedded (FFPE) tissue, or unstained marrow aspirate or PB specimens obtained and prepared from PB, BM aspirate, or other involved tissues for molecular or genetic studies in which the use of such material has been validated. (
  • The only one of its kind in the Caucasus region, the Stem Cell Harvesting Center features a state-of-the-art tissue-typing laboratory, and can store and harvest stem cells provided by healthy bone marrow donors. (
  • Sibling cord blood and bone marrow transplantation has similar outcome. (
  • The result of unrelated-donor bone marrow transplantation is in general inferior but extended HLA matching may improve outcome. (
  • Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. (
  • Poor outcome with hematopoietic stem cell transplantation for bone marrow failure and MDS with severe MIRAGE syndrome phenotype. (
  • Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study. (
  • The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients. (
  • These researchers concluded that high-dose chemotherapy with autologous stem cell transplantation is an effective and safe treatment option for patients younger than 60 years with poor prognosis advanced follicular lymphoma, even in facilities that perform few transplants per year. (
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (
  • Furthermore, this procedure may be safely performed in clinical centers that perform fewer than 3 autologous stem cell transplants a month. (
  • In addition, it was previously thought that this procedure could only be safely performed in a large institute that performed many stem cell transplants per year. (
  • By this strategy the time interval for donor search can be significantly prolonged leading to a higher proportion of success.Nevertheless, not every patient initially eligible for transplantation undergoes this procedure subsequently. (
  • Autologous peripheral blood stem cell transplantation, which attempts to eradicate minimal residual disease with myeloablative chemotherapy and rescue by autologous stem cells (collected from peripheral blood in the previous treatment procedure) to restore bone marrow function, has been included in the standard treatment regimen of high-risk neuroblastoma. (
  • In this way we hope to push back the frontier of cord blood transplantation, and make the procedure both safer and available to more patients. (
  • Los Angeles, June 19, 2010 - The Armenian Bone Marrow Donor Registry (ABMDR) announced that, for the first time in the history of Armenia and the Caucasus region, it has performed a stem cell harvesting procedure in Yerevan. (
  • Dr. Jordan continued: "The procedure is also an outstanding achievement for Armenia, which is already being recognized as an important international center for stem cell harvesting. (
  • The stem cell harvesting procedure in Yerevan was performed on June 16, at the ABMDR's Stem Cell Harvesting Center, collecting stem cells from a healthy donor. (
  • The procedure, which is painless and non-intrusive, was supervised by doctors Andranik Meshetsian and Mihran Nazaretyan of the Stem Cell Harvesting Center. (
  • Once the procedure was completed and qualitative and quantitative lab tests verified that the harvesting was conducted in accordance with international standards, the stem cell harvest was entrusted to a specialist courier who had traveled to Yerevan for this purpose. (
  • The only cure is a well-matched stem cell transplantation, but this procedure is not widely available to everyone. (
  • Autologous transplants are used less frequently than allogeneic transplants for AML patients mainly because of the lack of a graft-versus-leukemia effect and the risk of returning some leukemia cells back to the patient. (
  • Nearly 40% of patients were treated at small institutions that performed 31 or few autologous stem cell transplants per year for blood-related cancers. (
  • In year one of this award we completed the major objectives of Aim1, namely to explore the survival, integration, and cell fate of stem cell-derived MGE cell transplants in the uninjured rodent spinal cord. (
  • T cell-depleted transplants, higher baseline serum albumin, and non-Hispanic ethnicity were associated with lower risk of AKI. (
  • T cell-depleted hematopoietic cell transplants and higher serum albumin had lower risk of AKI. (
  • Mobilization of lymphokine activated killer cells (LAK), use of blood stem cells (BSC) for allogeneic transplants and ex vivo expansion of the mobilized cells are emerging as the future areas for research. (
  • Our group has developed a strategy called "dual" or "haplo-cord" transplants: patients receive stem cells from a single cord blood unit combined with stem cells from the bone marrow of a donor who is "haploidentical" to the patient. (
  • Access to transplantation is limited in low- and many medium-income countries, where the rate of transplants remains far below that of richer nations. (
  • The stem cells subsequently can be utilized in transplants for patients suffering from life-threatening blood-related diseases such as leukemia and other cancers. (
  • Established in 1999, the ABMDR, a nonprofit organization, helps Armenians worldwide survive life-threatening blood-related illnesses by recruiting and matching donors to those requiring bone marrow stem cell transplants. (
  • Those in the blood stream are called peripheral blood stem cells (PBSCs). (
  • This study aimed to analyze the efficacy of autologous peripheral blood stem cell transplantation for high-risk neuroblastoma in China. (
  • The results of survival analysis showed that autologous peripheral blood stem cell transplantation based on this pretreatment regimen significantly improved the prognosis of children in the high-risk group. (
  • Based on this pretreatment programme, autologous peripheral blood stem cell transplantation is safe and tolerable and significantly improves the prognosis of children in the high-risk group. (
  • A series of studies on autologous peripheral blood stem cell transplantation have been published, however, these have rarely been conducted in China [ 6 ]. (
  • This study, based on 10 years of clinical experience in our centre, retrospectively analyzed the data of high-risk neuroblastomas treated by the CCCG-NB-2015 regimen and summarized the efficacy and safety of autologous peripheral blood stem cell transplantation, including single transplantation and tandem transplantation. (
  • Here, we report transmission of dengue virus to a peripheral blood stem cell recipient by a donor who had recently traveled to an area to which the virus is endemic. (
  • As with all treatments, the doctor's job is to remove obstacles so that cells of the patient can get on with the business of healing the patient. (
  • For example, in developing and developed countries alike, kidney transplantation not only yields survival rates and quality-of-life that are far superior to those obtained with other treatments for end-stage renal disease, such as haemodialysis, but is also less costly in the long run. (
  • While most cell-based treatments for diabetes aim to replace lost or dysfunctional pancreatic β cells (the cells which produce insulin), some studies have suggested that transplanted cells can also stimulate the regeneration of the β cell population, and in so much, represents an alternative strategy to treat diabetes. (
  • Bile ducts act as the liver's waste disposal system, and malfunctioning bile ducts are behind a third of adult and 70 percent of children's liver transplantations-there are currently no alternative treatments, which is a problem given the shortage of liver donors. (
  • A University of South Florida spin-out, Saneron-CCEL Therapeutics is a subsidiary of CRYO-CELL International, Inc. In late 2001 the firm had merged with Saneron Therapeutics, Inc., to become Saneron CCEL Therapeutics, Inc. The company has been granted patents in many countries throughout the world for the therapeutic use of sertoli cells. (
  • He has received the 2013 Van Bekkum Award, the most prestigious European Blood and Marrow Transplantation (EBMT) award for the best abstract submitted to the physician''s programme. (
  • Better differential prognostic factors more reliably identify patients in first remission who should be treated with transplantation. (
  • For some patients who are in remission and can tolerate intensive chemotherapy, the doctor may recommend stem cell transplantation during the consolidation phase of chemotherapy. (
  • Research to determine which patients are most likely to benefit from stem cell transplantation after their first complete remission is evolving. (
  • Sickle cell disease (SCD) is one of the most prevalent monogenic disease in the world caused by a one point mutation at position 6 of the β-globin gene, which results in abnormal production of hemoglobin S ( 1 - 3 ). (
  • Those studies can help identify various causes of splenomegaly, such as sickle cell disease, spherocytosis, and other hereditary hemolytic anemias. (
  • He was born with sickle cell disease, an inherited red blood cell disorder. (
  • Sickle-cell disease (SCD) is an inherited disorder of haemoglobin. (
  • Sickle-cell disease (SCD) is a genetic condition in which the red blood cells contain haemoglobin S (HbS), an abnormal form of the oxygen-carrying protein. (
  • Sickle-cell disease prevalence depends on sickle-cell trait. (
  • Sickle cell disease is a group of red blood cell disorders passed by genes from parents to their children. (
  • Most children with sickle cell disease are pain-free between pain crises, but adolescents and adults may suffer from ongoing pain. (
  • Approximately 100,000 Americans have sickle cell disease. (
  • About one in every 365 black children is born with sickle cell disease. (
  • Learn how you can participate in NHLBI clinical trials related to sickle cell disease on NHLBI's website. (
  • Sickle cell disease is a lifelong illness. (
  • It is a growing option for people with sickle cell disease. (
  • NHLBI researchers are studying the genetic factors behind sickle cell disease. (
  • This includes fetal hemoglobin, which protects an infant from sickle cell disease for the first six months after birth. (
  • Researchers in Japan who evaluated the risks and efficacy of transplanting two varieties of stem cells into mouse cochlea have concluded that both adult-derived induced pluripotent stem (iPS) cells and mouse embryonic stem (ES) cells demonstrate similar survival and neural differentiation capabilities. (
  • Consequently, this study compared the survival and neural differentiation capabilities of ES and three clones of mouse iPS cells. (
  • While this study did not look at the ability of the transplanted cells to repair hearing loss, it does provide insight into the survival and fate of transplanted cells. (
  • To compare the event-free survival at 2 years of CPX-351 vs. conventional care regimens before allogeneic blood cell transplantation as first line treatment in patients with higher risk MDS and oligoblastic AML. (
  • It has been shown that MSC transplantation markedly improved animal survival as well as functional and morphological parameters of cisplatin-induced AKI [ 4 - 8 ]. (
  • Also, we initiated histological examination of animals six months post-injection and detected robust human cell survival, dispersal into the spinal cord grey matter, and neuronal maturation, but no evidence of tumor formation. (
  • Our preliminary histological analysis shows robust human cell survival, distribution, and neuronal differentiation, and we have electrophysiological data indicating functional integration of the transplanted cells. (
  • Patients in the trial, Scleroderma: Cyclophosphamide or Transplantation (SCOT), experienced improved event-free and overall survival. (
  • The 3-year event-free survival (EFS) and overall survival (OS) rates for the transplantation group and the nontransplantation group were 65.5% vs. 41.3% ( p =0.023) and 77.1% vs. 57.9% ( p =0.03), respectively. (
  • Conclusions: Discouraging survival rates in patients treated early after allogeneic hematopoietic stem cell transplantation do not support the use of extracorporeal membrane oxygenation for acute respiratory distress syndrome in this group. (
  • Access to transplantation entails more than the surgery itself, because success is measured by longer survival of the patient and a long-term improvement in the quality of life. (
  • In the future, both cell types can be the substrate for chemical screens to identify molecules that enhance MN survival. (
  • An active basic science community and an efficient translation of innovation into the clinic are crucial for the future of transplantation medicine. (
  • Antithymocyte globulin (ATG) has been successfully used for decades in clinical transplantation due to its immunosuppressive role in GVHD and solid organ rejection. (
  • Tacrolimus is a potent immunosuppressive drug widely used to prevent and treat graft-versus-host disease (GVHD) in stem cell transplantation (SCT). (
  • Various clinical trials using hepatocyte transplantation have demonstrated partial improvement of liver function. (
  • Clinical trials have been conducted to test a variety of strategies in which CD4+ T or stem cells are obtained from a patient, the CCR5 gene is either mutated or its translation blocked by RNA interference, and then the resulting virus-resistant cells are returned to the patient. (
  • HLA-haploidentical hematopoietic stem cell transplantation is now one of the most commonly employed alternative donor techniques, with most centers applying T-cell-replete strategies such as that developed by the Baltimore group using high-dose posttransplant cyclophosphamide. (
  • HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and does not require graft manipulation or storage, which results in a low graft acquisition cost. (
  • Several large, registry-based retrospective studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation. (
  • McCurdy, SR & Luznik, L 2019, ' How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide ', Blood , vol. 134, no. 21, pp. 1802-1810. (
  • Few studies are reported on the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation in mice with AD and on the effect on oxidative injury and neurogenesis in the brain of AD mice. (
  • Background: Haematopoietic stem cell transplantation constitutes a therapeutic choice for the treatment of a number of paediatric diseases. (
  • Via reselecting cells with high aldehyde dehydrogenase (ALDH) activity, a cytosolic detoxification enzyme highly expressed in progenitors [4], the authors now show that reselected UCB-HPCs may represent an improved therapeutic option. (
  • Previous studies by this group had suggested that ALDHhi cells form the UCB may be therapeutically relevant [5, 6] and, in this new study, they prove that expansion and reselection of these cells represents a practical means with which to produce the quantity of cells required for therapeutic application. (
  • Can reselection of other stem cells extend their therapeutic relevance? (
  • Allogeneic transplantation uses healthy blood-forming cells from an HLA-matched family member, an unrelated donor, or from umbilical cord blood. (
  • The company's patented technology includes U-CORD-CELL from umbilical cord blood, which is a stem cell technology, as well as SERT-CELL from Sertoli cells. (
  • Saneron has patented and patent-pending technology relating to our platform technology of: * U-CORD-CELLTM - Umbilical cord blood * SERT-CELLTM - Sertoli cells. (
  • Another advantage of cord blood stem cells is that they can be available in much less time than it takes to activate a registered bone marrow donor. (
  • 1 This includes human cells for transplantation such as haematopoietic stem cells from bone marrow, peripheral blood or cord blood. (
  • Red blood cells are removed from the cord blood. (
  • Intrapancreatic delivery of human umbilical cord blood aldehyde dehydrogenase-producing cells promotes islet regeneration. (
  • 1. The Society bears the name: European Society for Organ Transplantation, henceforth referred to as: ESOT. (
  • Given the chronic shortage of donor organs, it's important to look at ways of repairing damaged organs, or even provide alternatives to organ transplantation," said Fotios Sampaziotis of the Wellcome-MRC Cambridge Stem Cell Institute. (
  • This is because patients receive their own stem cells, so the risk of some complications, such as graft-versus-host disease, is lower. (
  • Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. (
  • TNF, LTA and TGFB1 genotype distributions among acute graft-vs-host disease subsets after HLA-matched unrelated hematopoietic stem cell transplantation: a pilot study. (
  • [ 84 ] Improved identification of closely matched unrelated donors, modifications of myeloablative preparation and reduced intensity regimens now make transplantation safely available to more patients. (
  • In January, Keith M. Sullivan, MD, professor of medicine at Duke University Medical Center in Durham, N.C., and colleagues reported in the New England Journal of Medicine that myeloablative autologous hematopoietic stem cell transplantation resulted in long-term benefits for patients with severe scleroderma. (
  • Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. (
  • Cite this: Treatment of Acute Myeloid Leukemia With Hematopoietic Stem Cell Transplantation - Medscape - May 01, 2009. (
  • Allogeneic stem cell transplantation, compared to other treatment approaches, is associated with a higher rate of side effects and mortality in patients. (
  • If there is evidence of Epstein-Barr virus (EBV)-driven disease, including hemophagocytic lymphohistiocytosis (HLH), treatment with a monoclonal anti-CD20 antibody (rituximab) can be used to deplete the B cell population harboring the virus. (
  • Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. (
  • One serious side effect that is common with the treatment of high doses of chemotherapy involves the suppression of blood cells. (
  • One common approach to 'bridge' higher-risk MDS from the time of diagnosis to transplantation is a treatment with hypomethylating agents such as azacitidine due to its anticipated low toxicity profile. (
  • From the past six months of work, we report considerable progress toward our aims of investigating the safety and efficacy of human inhibitory nerve precursor (MGE) cell transplantation for the treatment of spinal cord injury-induced bladder spasticity and neuropathic pain. (
  • The rates of treatment-related death and post-transplantation use of disease-modifying anti-rheumatic drugs (DMARDs) were lower than previous studies of nonmyeloablative transplantation. (
  • Dr. Sullivan and colleagues are particularly interested in this subset of patients and think the benefits of stem cell treatment outweigh its risks for these patients. (
  • The trial demonstrated the durability of the beneficial effects of the stem cell treatment. (
  • Since 2010, our centre is the first in China to lead the use of tandem autologous stem cell transplantation for the treatment of high-risk neuroblastoma, the related procedures and conditioning protocols for stem cell collection, storage and reinfusion have been developed and incorporated into the high-risk neuroblastoma standard treatment regimen, known as the Chinese Children's Cancer Group (CCCG) Neuroblastoma (NB)-2015 regimen. (
  • Hepatocyte transplantation has been proposed as an alternative to orthotopic liver transplantation for treatment of patients with acute liver failure (ALF) and metabolic disorders. (
  • Lastly, clinical data from patients with macular degeneration treated with hESC-derived retinal cells have demonstrated that hESCs may provide a potentially safe renewable and reliable source of cells for the treatment of various disorders [ 4 ]. (
  • To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). (
  • Moreover, for patients who have kidney failure, access to transplantation is reduced when funds are spent on other forms of treatment that are less cost-effective. (
  • During the reporting period, we completed histological analyses for the two-month time point post-injection, and we found that the human MGE cells, derived from human embryonic stem cells (hESCs), appropriately matured into forebrain-type inhibitory interneurons in the rodent spinal cord. (
  • Moreover, the preclinical studies employed to assess safety and function of human embryonic stem cell (hESC)-derived hepatocytes are generally limited to immunodeficient mice. (
  • Conclusions: Among patients who underwent alloHCT and lived to 100 days, the majority did not report regretting their transplantation. (
  • A working group formed by the Public Health Service (PHS) in 1991 to address these issues concluded that further recommendations should be made to reduce the already low risk of HIV transmission by transplantation of organs and tissues. (
  • This occurrence raised questions about the need for additional federal oversight of transplantation of organs and tissues. (
  • The working group concluded that, although existing recommendations are largely sufficient, revisions should be made to reduce the already low risk of HIV transmission via transplantation of organs and tissues. (
  • Nonetheless, the transplantation of organs and tissues does raise ethical concerns. (
  • In addition to recruiting bone marrow donors, these events will seek support for the establishment of a stem cell transplantation center in Armenia and the creation of support groups in Australia, Egypt, France, Latin America, and Russia. (